SunBio, Inc. Logo

SunBio, Inc.

Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.

067370 | KO

Overview

Corporate Details

ISIN(s):
KR7067370007
LEI:
Country:
South Korea
Address:
인천광역시 남동구 은봉로 129 -, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SunBio, Inc. is a biotechnology company that develops, produces, and commercializes biosimilars, biopharmaceuticals, and medical devices. The company's core research and development activities are based on its proprietary PEGylation technology, a platform used to enhance the efficacy and duration of therapeutic drugs. Key products in its pipeline include an artificial blood substitute and MucoPEG, a treatment for xerostomia (dry mouth).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 61.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-07 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.7 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.5 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-24 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.8 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 353.1 KB
2025-03-21 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 94.4 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 18.8 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2024-12-11 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all SunBio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SunBio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SunBio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia
SKF

Talk to a Data Expert

Have a question? We'll get back to you promptly.